In this episode of the Diabetes Innovators Series, Rob interviews Dr. Viral N Shah discussing the Adjust T1D trial, which investigates the effects of semaglutide, a GLP-1 agonist, on adults with type 1 diabetes. The trial aims to explore adjunctive treatment options beyond insulin, focusing on improving glycemic control, weight loss, and overall patient outcomes. Dr. Shah shares insights on the trial's design, results, safety profile, and implications for future diabetes management, emphasizing the need for continued research and community support.
Chapters
00:00 Introduction to the Adjust T1D Trial
03:06 Understanding Type 1 Diabetes and Treatment Options
05:46 Results of the Adjust T1D Trial
08:54 Safety and Efficacy of Semaglutide
11:45 Implications for Type 1 Diabetes Management
14:52 Future Research and Community Impact
Resources:
